Atlas Trials

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Clinical trial NCT05930665 · UNKNOWN

Trial details

NCT number
NCT05930665
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pleural Mesothelioma
Start date
2023-11-01
Primary completion
2025-07-01
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.